Xponance Inc. Invests $186,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Xponance Inc. purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,151 shares of the biopharmaceutical company’s stock, valued at approximately $186,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its position in shares of ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after buying an additional 1,966,607 shares during the last quarter. Barclays PLC lifted its position in ACADIA Pharmaceuticals by 126.2% in the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock valued at $4,269,000 after acquiring an additional 154,854 shares during the last quarter. Burney Co. acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at $6,953,000. Proficio Capital Partners LLC purchased a new position in shares of ACADIA Pharmaceuticals during the fourth quarter worth about $272,000. Finally, BNP Paribas Financial Markets increased its position in shares of ACADIA Pharmaceuticals by 259.0% during the third quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock worth $3,439,000 after purchasing an additional 161,331 shares in the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares of the company’s stock, valued at $320,756.85. The trade was a 21.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Mark C. Schneyer sold 3,171 shares of the stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the completion of the sale, the executive vice president now directly owns 56,889 shares in the company, valued at approximately $969,957.45. The trade was a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,433 shares of company stock worth $187,319 over the last 90 days. Company insiders own 28.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $23.93.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock opened at $17.07 on Friday. ACADIA Pharmaceuticals Inc. has a one year low of $14.15 and a one year high of $20.68. The company has a market cap of $2.85 billion, a P/E ratio of 21.88 and a beta of 0.43. The business has a fifty day moving average of $18.34 and a two-hundred day moving average of $17.04.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.